Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Barclays PLC

Barclays PLC grew its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 273.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,295 shares of the company’s stock after buying an additional 58,776 shares during the quarter. Barclays PLC owned about 0.11% of Ventyx Biosciences worth $175,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Palumbo Wealth Management LLC acquired a new position in Ventyx Biosciences during the third quarter worth $26,000. China Universal Asset Management Co. Ltd. raised its holdings in Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the last quarter. Intech Investment Management LLC acquired a new position in Ventyx Biosciences during the third quarter worth $42,000. The Manufacturers Life Insurance Company raised its holdings in Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Ventyx Biosciences during the second quarter worth $58,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VTYX. HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.00.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $2.16 on Thursday. The stock has a fifty day moving average of $2.27 and a two-hundred day moving average of $2.27. The company has a market capitalization of $152.73 million, a price-to-earnings ratio of -0.92 and a beta of 0.55. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48.

Insiders Place Their Bets

In other Ventyx Biosciences news, CEO Raju Mohan acquired 261,752 shares of the stock in a transaction dated Monday, November 25th. The stock was acquired at an average price of $2.01 per share, with a total value of $526,121.52. Following the completion of the transaction, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction on Friday, December 27th. The shares were sold at an average price of $2.36, for a total value of $49,840.84. Following the completion of the sale, the insider now directly owns 464,582 shares of the company’s stock, valued at approximately $1,096,413.52. This represents a 4.35 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 630,000 shares of company stock valued at $1,262,415. Corporate insiders own 18.18% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.